2月11日 - ** 药物开发商Upstream Bio UPB.O的股票在盘前交易中上涨20%，达到32.64美元
** 公司称其试验性哮喘药物Verekitug在一项中期研究中减少了严重的哮喘发作
** 该药物在低剂量时可将每年的哮喘发作次数减少 56%，在高剂量时减少 39%，并改善了肺功能 - UPB
** 副作用与早期研究相似；90%以上符合条件的患者参加了长期扩展研究，公司表示
** 在与监管机构进行谈判后，UPB 计划对严重哮喘和慢性鼻窦疾病进行后期试验
** 2025 年股价上涨约 65%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.